You are here: Industry Insights > cardiovascular

News List

Inflammation Testing Prompts Care Changes Leading to Significantly Lower Levels in Patients with Increased Cardiovascular Risk Due to Diabetes or Pre-Diabetes biospace
March 28, 2018
New research finds that patients with diabetes, pre-diabetes or no evidence of diabetes whose physicians ordered myeloperoxidase (MPO) inflammation testing achieved sharp reductions in MPO levels over five years.
Intact Vascular Welcomes TOBA BTK Trial One-Year Clinical Study Results Publication in Catheterization and Cardiovascular Intervention Intact Vascular Welcomes TOBA BTK Trial One-Year C
March 28, 2018
Intact Vascular, Inc.today welcomed the publication of the Tack Optimized Balloon Angioplasty Below the Knee (TOBA BTK) clinical trial results in the current issue of Catheterization and Cardiovascular Intervention.
Philips provides University of Ottawa Heart Institute with innovative health technology solutions for their expanded cardiovascular care facility biospace
March 26, 2018
Royal Philips offers a wide range of health technology solutions to UOHI, the largest and most important heart health centre in Canada, dedicated to understanding, and preventing heart disease
BioVentrix Announces First Patient at Cardiovascular Institute of the South Successfully Treated in biospace
March 13, 2018
BioVentrix, Inc today announced successful treatment of the first patient at the Cardiovascular Institute of the South in the ALIVE pivotal clinical trial.
Amgen's Repatha Reduces Cardiovascular Events in Patients with a History of Heart Attacks biospace
November 16, 2017
Repatha, Amgen's PSCK9 inhibitor, continues to impress as a treatment for patients with peripheral artery disease (PAD) and a history of heart attacks
Anacetrapib reduces risk of serious cardiovascular events europeanpharmaceuticalreview
August 30, 2017
An international clinical trial has assessed the efficacy and safety of adding anacetrapib versus placebo atorvastatin in patients with vascular diseases…
Victoza reduces the risk of major cardiovascular events in type 2 diabetes patients biospectrumasia
August 30, 2017
This post-hoc analysis was presented at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain.
Victoza indicated to reduce the risk of three major adverse cardiovascular events biospectrumasia
August 28, 2017
The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in adults with type 2 diabetes and established CV diseas
Light-to-moderate alcohol consumption may have protective health effects worldpharmanews
August 16, 2017
Light-to-moderate drinking can lower risk of mortality from all-causes and cardiovascular disease, while heavy drinking can significantly increase risk of mortality from all-causes and cancer
Takeda and Cardurion Form Cardiovascular Partnership contractpharma
August 04, 2017
Collaboration to develop novel, next-generation therapeutics to treat heart disease

Previous page 1 2 3 4 5 6 7 8 9 10 Next page